Biotech financing puts pharma M&A in the shade, report finds

Money flooded into initial public offerings (IPOs) and venture financing for young biotech companies in the first half of 2018, according to a report by Vantage, the editorial arm of the intelligence firm Evaluate.

Such financing increased from the healthy levels of the previous year, with a record $3.5 billion raised in IPOs across western stock exchanges, says Vantage’s Pharma, Biotech and Medtech Half-year Review 2018.

"Larger drugmakers are desperate for innovation, which is becoming increasingly expensive"